Biotech Values

[dav1234]

Shares of Anadys (ANDS) Trade Above $1; Analyst Believes Co. Could Get a Bid Following Setrobuvir Data
Oct 6, 2011
William Blair's Katherine Xu believes Anadys Pharma (Nasdaq: ANDS) may be acquired following the release of top-line 12-week Setrobuvir Phase IIb data sometime next week (or by mid-October at the latest). The analyst attaches a 50 percent chance of a buyout.

Xu notes Johnson & Johnson (NYSE: JNJ), Boehringer Ingelheim, GaxoSmithKline (NYSE: GSK) and Novartis (NYSE: NVS) are all possible suitors for the acquisition.

William Blair has an Outperform rating and $4 price target on shares of Anadys.

Shares of ANDS are trading up 7.1 percent to just barely over $1. Notably, the stock has not traded over this level since the beginning of August.


pretty good call by this analyst,lol

http://www.streetinsider.com/Analyst+Comments/Shares+of+Anadys+%28ANDS%29+Trade+Above+%241%3B+Analyst+Believes+Co.+Could+Get+a+Bid+Following+Setrobuvir+Data/6839646.html